The FIRE AND ICE Trial: What We Know, What We Can Still Learn, and What We Need to Address in the Future

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023884%3A_____%2F18%3A00008050" target="_blank" >RIV/00023884:_____/18:00008050 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1161/JAHA.118.010777" target="_blank" >http://dx.doi.org/10.1161/JAHA.118.010777</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1161/JAHA.118.010777" target="_blank" >10.1161/JAHA.118.010777</a>

Result language
angličtina
Original language name
The FIRE AND ICE Trial: What We Know, What We Can Still Learn, and What We Need to Address in the Future
Original language description
The FIRE AND ICE Trial (ClinicalTrials.gov, identifier NCT01490814) was initiated in 2012 as a multicenter, randomized, head‐to‐head comparison of radiofrequency current (RFC) and cryoballoon catheter ablation for the treatment of patients with drug‐refractory symptomatic paroxysmal atrial fibrillation (AF). Six years on, it remains the largest, randomized comparison of safety and efficacy between 2 catheter ablation modalities used in the treatment of patients with AF. This landmark trial not only established noninferiority between cryoballoon and RFC ablation for pulmonary vein isolation (PVI) with regard to the study's efficacy and safety primary end points,1 but also, it evaluated secondary end points that were critical for a representative study interpretation.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems

Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)